Simultaneous expression of CD13, CD22 and CD25 is related to the expression of Fc epsilon R1 in non-lymphoid leukemia.
Like CD19 or CD56, CD22 in non-lymphoid leukemia has been considered an aberrantly expressed antigen. CD22 had been believed to be restricted to B lymphoid, however, it was also found to be expressed in human basophils. Mature basophils are unique granulocytes expressing CD13, CD22 and CD25. To estimate whether the expression of CD22 in non-lymphoid leukemia is aberrant or related to basophilic character, we analyzed 108 patients with primary and secondary leukemia. Among non-lymphoid leukemias, surface CD22 expression was more frequently observed in peroxidase-negative AML and secondary leukemia, and was usually observed simultaneously with CD13 and CD25. Samples obtained from 17 cases were further analyzed, and all the Fc epsilon R1-positive cases were observed in peroxidase-negative AML and secondary non-lymphoid leukemia, and mostly expressed CD13, CD22 and CD25. Therefore, surface CD22 expression in non-lymphoid leukemia was thought to relate to basophilic phenotype in some cases. Like CD22, some of the so-called aberrantly expressed antigens may not actually be aberrant, but are expressed in a stage of differentiation and maturation of progenitors. Moreover, CD22 may be one of target molecules for treatment of CD22-positive, poorly prognostic leukemia.
Sato
Naoko
N
First Department of Internal Medicine, Niigata University Medical and Dental Hospital, Asahimachi-dori 1, Niigata City 951-8520, Japan. nao24@maple.ocn.ne.jp
Kishi
Kenji
K
Toba
Ken
K
Watanabe
Kenichi
K
Itoh
Hiromi
H
Narita
Miwako
M
Takahashi
Masuhiro
M
Aizawa
Yoshifusa
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis; D001491:Basophils / Q000276:immunology / Q000473:pathology; D018826:CD13 Antigens / Q000032:analysis; D015815:Cell Adhesion Molecules; D002648:Child; D002675:Child, Preschool; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D007231:Infant, Newborn; D037102:Lectins / Q000032:analysis; D007938:Leukemia / Q000175:diagnosis / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000276:immunology / Q000473:pathology; D017455:Receptors, IgE / Q000032:analysis*; D015375:Receptors, Interleukin-2 / Q000032:analysis; D051918:Sialic Acid Binding Ig-like Lectin 2
D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; C497867:CD22 protein, human; D015815:Cell Adhesion Molecules; D037102:Lectins; D017455:Receptors, IgE; D015375:Receptors, Interleukin-2; D051918:Sialic Acid Binding Ig-like Lectin 2; D018826:CD13 Antigens